Rare diseases
Investigational molecules
Locations
1007 Slater Road Suite 250, 27703-5423, United States
Priovant Therapeutics Inc. is involved in clinical research for dermatomyositis, with a focus on adult patients affected by this rare autoimmune myopathy. The sponsor’s work in this area centers on treatment options for muscle weakness, skin involvement, and broader inflammatory disease activity.
The company’s clinical activity in this field reflects interest in therapies that address complex systemic inflammation and functional decline associated with idiopathic inflammatory myopathies.
Priovant Therapeutics Inc. runs clinical trials in conditions such as Cutaneous sarcoidosis, Dermatomyositis, Uveitis, Chorioretinitis, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis
FranceA study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe
BelgiumStudy on the Effects of Brepocitinib and Prednisone for Adults with Active Non-Infectious Uveitis
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
